Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

142.60USD
12 Dec 2017
Change (% chg)

$1.46 (+1.03%)
Prev Close
$141.14
Open
$142.21
Day's High
$143.56
Day's Low
$142.04
Volume
3,581,204
Avg. Vol
1,731,414
52-wk High
$144.34
52-wk Low
$110.76

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

GSK, other drugmakers bet on post-Brexit UK science

LONDON Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

06 Dec 2017

GSK, other drugmakers bet on post-Brexit UK science

LONDON Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

06 Dec 2017

Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

05 Dec 2017

Jury orders Bayer, Johnson & Johnson to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million (£20.70 million) to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

05 Dec 2017

UPDATE 1-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

05 Dec 2017

CORRECTED-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks by its blockbuster drug Xarelto.

05 Dec 2017

Breakingviews - Consumer groups’ health drive comes at a cost

LONDON (Reuters Breakingviews) - Over-the-counter drugs could pose health risks for investors in consumer groups. Germany’s Merck has invited bids for its Seven Seas vitamins unit, while Pfizer is selling its more consumer-focused business. Nestlé and rivals see opportunities to apply their sharper marketing skills. But pumped-up valuations suggest the health drive will be expensive.

04 Dec 2017

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Earnings vs. Estimates